Malaysian Biotech Licenses Technology For Non-Cancer Therapy (Malaysia)
This article was originally published in PharmAsia News
Executive Summary
Malaysia's Biotechnology Corp. says it has made its first technology licensing agreement, with the French start-up Nanobiotix. The cost of the deal was not disclosed. Nanobiotix makes nanotechnology applications for cancer therapy. Biotech intends to license the nanotechnology for purposes other than cancer, the firm's current primary focus. Nanobiotix CEO Laurent Levy said the agreement would allow it to expand its pipeline into non-cancer areas. (Click here for more
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.